[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100088389":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":25,"locations":33,"responsibleParty":53,"collaborators":56,"id":60,"slug":25,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"pyridostigmine","ACTIVE_COMPARATOR","Active study drug",[13],"Drug: pyridostigmine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Control",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","one 180 mg capsule per day for 3 days",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"one capsule per day for 3 days",[15],[30],{"name":31,"affiliation":5,"role":32},"Wolfgang Singer, M.D.","PRINCIPAL_INVESTIGATOR",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Rochester","Minnesota","55905","United States",{"type":41,"coordinates":42},"Point",[43,44],-92.4699,44.02163,{"lat":44,"lon":43},[47,52],{"name":48,"role":49,"phone":50,"phoneExt":25,"email":51},"Toni Gehrking","CONTACT","507-284-0336","adc.research@mayo.edu",{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Wolfgang Singer, MD","Principal Investigator",[57],{"name":58,"class":59},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100088389",false,"NCT00409435","A Study of Pyridostigmine in Postural Tachycardia Syndrome","Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome","Inclusion Criteria:\n\nDiagnosis of postural tachycardia syndrome using the following criteria:\n\n* Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.\n* Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.\n\nBoth criteria must be fulfilled.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study\n* Hypothyroidism or hyperthyroidism\n* Clinically significant coronary artery disease\n* Medications that could interfere with autonomic testing\n* Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month","ALL","15 Years","55 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.",[77],"Postural Tachycardia Syndrome",[79],"Postural tachycardia syndrome (POTS)","2026-03-03",{"date":82,"type":83},"2026-03-05","ACTUAL",{"date":85,"type":25},"2006-10",{"date":87,"type":71},"2027-02",{"name":5,"class":6},1]